DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
The same provider scores 4.6 on one site and 1.3 on another. Neither site is lying — they are surveying different people. Here is what each platform actually measures, and a direct link to every real review source we could verify.
The score is not the signal. The selection is.
Every review platform surveys a different slice of customers, and for GLP-1 telehealth the slices barely overlap. Trustpilot asks you the week your first vial arrives. BBB only hears from you if something went wrong enough to file. Reddit is the one place month-six users still talk — which matters, because GLP-1 problems are back-loaded: supply gaps, dose escalations, price jumps at higher doses, cancellation traps. Match the source to the question you actually have.
Unfiltered and unsolicited, but self-selected: people post when something goes wrong or unusually right, and the compounding subs skew ideological about FDA-approved vs compounded.
Read it for: Month 3+ experience — supply gaps, dose-escalation problems, what the vial actually looked like. The one place long-term users talk.
Skews negative by construction. Nobody files a BBB complaint to say things went fine, so the pool is people in a dispute. A low BBB score does not mean most customers are unhappy.
Read it for: The *pattern* in complaints. One billing dispute is noise; forty describing the same cancellation trap is the product.
Skews positive. Companies invite reviews right after purchase — before anyone has hit a refill, a dose escalation, or a cancellation. You are mostly reading week-one enthusiasm.
Read it for: Onboarding and shipping speed. Discount anything it says about long-term experience.
High noise floor and a weak verification process compared with the others.
Read it for: Corroborating a pattern you already saw on BBB — not for forming a first impression.
Built for B2B software. Consumer-healthcare coverage is thin and the reviewer base is not patients.
Read it for: Little. Treat any GLP-1 provider score here as close to meaningless.
We publish no aggregate review score. There is no verified way for us to source one, and an invented number would be a fake review under FTC 16 CFR Part 465 — so we link the platforms instead and tell you what each one’s reviews are worth. Where a provider has no real review profile, we say that too: the gap is itself worth knowing about.
telehealth
No third-party review profile
Reviews land on Amazon-the-retailer, not on the pharmacy, so they measure delivery — not prescribing. For the clinical side, the useful fact is that One Medical names a board-certified chief medical officer with a public provider profile; check him, not the star rating.
retail pharmacy
No third-party review profile
Costco pharmacy has no GLP-1-specific review profile, and Costco's general brand reviews say nothing about this programme. The telehealth half runs through Sesame — that is the entity whose reviews are worth reading.
compounded telehealth
No third-party review profile
Newer platform with a thin review base — which is not a mark against it, but it does mean reviews cannot yet tell you much. Ask instead who prescribes, and check that person yourself.
compounded telehealth
Read the reviews yourself
Henry does not publish a named clinical lead, so reviews are the only public signal about who treats you — which is exactly the situation where reviews are least able to tell you.
compounded telehealth
Read the reviews yourself
manufacturer direct
No third-party review profile
No review profile for the fulfilment service itself. Any rating you see attached to "LillyDirect" is really Eli Lilly the drugmaker. And if you use the bundled telehealth, your prescriber works for a partner company — review that partner, not Lilly.
compounded telehealth
Read the reviews yourself
Read these alongside the documented regulatory record — a Washington State licence restriction on Mochi's own compounding pharmacy tells you more about what is in the vial than any star rating will. See the record on the verification page below.
manufacturer direct
Read the reviews yourself
The only profile that exists is for Novo Nordisk the pharmaceutical company — which reviews a drugmaker, not a fulfilment service. It tells you nothing about how fast your vial ships. This is the standard trap with manufacturer-direct channels: the parent company's rating gets borrowed to imply the shipping service is good.
telehealth
Read the reviews yourself
Operating since 2017, so unlike the 2024-25 entrants there is a genuine multi-year record to read. Weight the older reviews — they are the closest thing to a long-term signal any GLP-1 telehealth brand has.
government
No third-party review profile
Too new for a meaningful review base, and a government channel does not accumulate one the way a DTC brand does. Judge it on the published price and the eligibility rules, not on sentiment.
Because the two sites collect reviews from different people. Trustpilot reviews are mostly solicited by the company right after purchase, so they capture week-one enthusiasm — before anyone has hit a refill, a dose escalation, or a cancellation. BBB is a complaints channel: nobody files a BBB report to say things went fine, so the pool is people already in a dispute. Both numbers are real. Neither is an average of all customers. Read the pattern in the complaints, not the score.
Reddit, for one narrow reason: it is the only place where people who are three, six, and twelve months in still post. GLP-1 problems are back-loaded — supply gaps, dose-escalation side effects, surprise price jumps at higher doses, and cancellation friction all land after the honeymoon window that Trustpilot captures. Just remember the compounding subs skew ideological about compounded versus FDA-approved.
No. We have no verified way to source an aggregate score, and a number we invented would look measured — which is worse than publishing nothing. Fabricated review scores also violate the FTC rule on fake reviews and testimonials (16 CFR Part 465). What we publish instead is every real review source we could verify, plus an honest read on what each one is worth.
Not by itself — but it changes what you should lean on. Manufacturer-direct channels like LillyDirect and NovoCare have no review profile of their own, so any rating you see is really the parent drugmaker's, which says nothing about how fast your vial ships. When reviews cannot help you, fall back on things that are checkable: does the platform name a clinical lead, and is there a documented FDA, court, or state-board action against it?
When reviews run out, switch to what is checkable: whether the platform names a clinical lead you can look up, and whether a regulator or court has taken a documented action against it. Both are on the provider verification pages, each linked to its primary source.